1. Cell Cycle/DNA Damage
  2. DNA/RNA Synthesis
  3. Bleomycin sulfate

Bleomycin sulfate 

Cat. No.: HY-17565 Purity: >98.0%
Handling Instructions

Bleomycin sulfate is a DNA synthesis inhibitor with potent antitumor activity.

For research use only. We do not sell to patients.

Bleomycin sulfate Chemical Structure

Bleomycin sulfate Chemical Structure

CAS No. : 9041-93-4

Size Price Stock Quantity
10 mM * 1 mL in Water USD 280 In-stock
Estimated Time of Arrival: December 31
10 mg USD 168 In-stock
Estimated Time of Arrival: December 31
50 mg USD 672 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 7 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


Bleomycin sulfate is a DNA synthesis inhibitor with potent antitumor activity.

IC50 & Target

DNA/RNA Synthesis[1]

In Vitro

Bleomycin (BLM) is chosen as the best-studied micronucleus (MN) inducers in human lymphocytes with different mechanisms of genotoxicity. The most frequent Bleomycin-induced DNA lesions are single and double strand breaks and single apuinic/apyrimidinic sites. At the same time Bleomycin is true radiomimetic compound, resembling almost completely the genetic effect of ionizing radiation[1]. The IC50 value of Bleomycin sulfate for UT-SCC-19A cell line is 4.0±1.3 nM. UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin (BLM); IC50 values are 14.2±2.8 nM and 13.0±1.1 nM, respectively[2]. Bleomycin (BLM) induces a significant increase in the percentage of aberrant cells (i.e., cells showing at least one aberration) and in the frequency of chromosomal aberrations per cell compare with control cultures 18 h after treatment (p<0.05)[3].

In Vivo

Bleomycin sulfate treatment (3.5-4.0 mg/kg; intra-tracheal) on day 0, body weights decreases by day 4 then increases by Day 7 through the end of the study[4].
Bleomycin sulfate (3.5-4.0 mg/kg; intra-tracheal) produces a statistically significant increase in lung hydroxyproline levels, and also increases right caudal lung lobe mass[4].
A short-range beta-emitting radionuclide combined to Bleomycin (In-111-BLMC) is a tumor-targeting agent in SCCs. Within 35 days the weight of nude mice increases 2.8±0.6g. At 25 and 35 days after tumor inoculations the tumor volumes are 111±51 mm3 and 874±577 mm3, respectively. The calculated doubling time is 3.86±0.76 days. SCC cell lines demonstrate different sensitivity to Bleomycin. Our SCC tumor xenograft model shows a rapid growth proper for radiochemotherapeutic studies using In-111-BLMC. The uptake of In-111-BLMC in vivo has been directly proportional to proliferation activity, and the tumors with high binding capacity could be predicted from animal model dose calculations[2]. At 7 and 14 days after Bleomycin (BLM) treatment, the signal of TGF-β1 is significantly stronger than that of the control group. At 28 days after treatment, the TGF-β1 signal became a little weaker. At 7 and 14 days of Bleomycin plus Dex group, the signal of TGF-β1 is also stronger than that of the control group. However, at 28 days, the TGF-β1 signal become weaker and is a little stronger than the level of control group. All the results are given by comparison of the average IOD value[5].

Animal Model: Male Fischer 344 rats, 8–10 week old, weighing 150-250 g[4]
Dosage: 3.5-4 mg/kg
Administration: Intra-tracheal
Result: Body weights decreased by day 4 then increased by Day 7 through the end of the study.
Clinical Trial
Molecular Weight







NC(C[[email protected]](NC[[email protected]@H](N)C(N)=O)C1=NC(N)=C(C)C(C(N[[email protected]](C(N[[email protected]@H](C)[[email protected]@H]([[email protected]@H](C)C(N[[email protected]@H](C(NCCC2=NC(C3=NC(C(NCCC[S+](C)C)=O)=CS3)=CS2)=O)[[email protected]](O)C)=O)O)=O)C(C4=CNC=N4)O[[email protected]@H]5[[email protected]]([H])(O[[email protected]@H]6[[email protected]@H](O)[[email protected]@H](OC(N)=O)[[email protected]](O)[[email protected]@H](CO)O6)[[email protected]](O)[[email protected]@H](O)[[email protected]@H](CO)O5)=O)=N1)=O.[O-]S(=O)(O)=O


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 255 mg/mL (168.58 mM; Need ultrasonic and warming)

DMSO : 16.67 mg/mL (11.02 mM; Need ultrasonic)

DMF : < 1 mg/mL (insoluble)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.6611 mL 3.3055 mL 6.6110 mL
5 mM 0.1322 mL 0.6611 mL 1.3222 mL
10 mM 0.0661 mL 0.3306 mL 0.6611 mL
*Please refer to the solubility information to select the appropriate solvent.

Purity: >98.0%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


BleomycinDNA/RNA SynthesisBacterialInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product name:
Bleomycin sulfate
Cat. No.:
MCE Japan Authorized Agent: